Signaturefd LLC Buys 1,032 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Signaturefd LLC grew its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 5.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 21,272 shares of the company’s stock after acquiring an additional 1,032 shares during the period. Signaturefd LLC’s holdings in Dr. Reddy’s Laboratories were worth $1,480,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. FSC Wealth Advisors LLC bought a new position in Dr. Reddy’s Laboratories during the third quarter valued at $40,000. Harbour Investments Inc. increased its position in shares of Dr. Reddy’s Laboratories by 2,884.6% during the third quarter. Harbour Investments Inc. now owns 776 shares of the company’s stock valued at $52,000 after buying an additional 750 shares during the period. Ronald Blue Trust Inc. boosted its position in shares of Dr. Reddy’s Laboratories by 84.8% in the third quarter. Ronald Blue Trust Inc. now owns 1,905 shares of the company’s stock valued at $120,000 after acquiring an additional 874 shares during the period. Tower Research Capital LLC TRC increased its holdings in Dr. Reddy’s Laboratories by 3,440.0% during the 3rd quarter. Tower Research Capital LLC TRC now owns 1,947 shares of the company’s stock worth $130,000 after acquiring an additional 1,892 shares during the period. Finally, Wells Fargo & Company MN lifted its stake in Dr. Reddy’s Laboratories by 103.5% in the 2nd quarter. Wells Fargo & Company MN now owns 3,064 shares of the company’s stock worth $193,000 after purchasing an additional 1,558 shares in the last quarter. Hedge funds and other institutional investors own 14.02% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on RDY shares. Barclays boosted their price objective on Dr. Reddy’s Laboratories from $75.00 to $80.00 and gave the stock an “overweight” rating in a report on Monday, January 29th. StockNews.com raised shares of Dr. Reddy’s Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 5th. Finally, Jefferies Financial Group cut shares of Dr. Reddy’s Laboratories from a “buy” rating to an “underperform” rating in a research report on Thursday, January 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Dr. Reddy’s Laboratories has a consensus rating of “Hold” and a consensus target price of $80.00.

Dr. Reddy’s Laboratories Price Performance

Shares of Dr. Reddy’s Laboratories stock opened at $71.14 on Monday. The firm has a market capitalization of $11.87 billion, a PE ratio of 18.77, a price-to-earnings-growth ratio of 1.77 and a beta of 0.58. The company has a current ratio of 2.55, a quick ratio of 1.90 and a debt-to-equity ratio of 0.02. Dr. Reddy’s Laboratories Limited has a 12 month low of $53.12 and a 12 month high of $77.72. The business’s 50-day moving average price is $74.44 and its 200-day moving average price is $70.27.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its quarterly earnings results on Wednesday, January 31st. The company reported $0.99 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.11. The business had revenue of $867.00 million for the quarter, compared to analysts’ expectations of $827.81 million. Dr. Reddy’s Laboratories had a net margin of 19.26% and a return on equity of 20.97%. Sell-side analysts forecast that Dr. Reddy’s Laboratories Limited will post 3.96 EPS for the current fiscal year.

About Dr. Reddy’s Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.